Skip to content
value.today

OncoMed

OMEDUnlisted company
No market cap data
Compare
World rank
—
no current market cap
Revenue
$44 M
For year ending December-2018
Net income
$-8 M
-18.2% margin
SEC filing
Employees
—

OncoMed in brief

OncoMed is an unlisted company in the Biotechnology industry, based in Redwood City, USA. It was founded in 2004. In the year to December 2018 it had sales of $44 M and a net loss of $8 M.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About OncoMed

OncoMed Pharmaceuticals, Inc. was a public American pharmaceutical development company headquartered in Redwood City, California. The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. As of 2013, the company had 83 employees. OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells". The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. OncoMed went public in 2013 and was listed on NASDAQ under the stock symbol OMED. In April 2019 the company was acquired by Mereo BioPharma and delisted from the Nasdaq.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

OncoMed timeline

3 events, 2004–2013
  1. 2004
  2. 🏁
    · approximate
    Founded
  3. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  4. 2013
  5. 🔔
    Initial public offering
    Final prospectus filed with the SEC on 18 July 2013; shares registered for exchange trading on 8 July 2013.

Events of OncoMed from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about OncoMed

Acquisitions and changes
Taken over: the company reported a change in control and the delisting of its shares to the SEC on 23 April 2019 (Form 8-K).

Market cap history

Not enough history yet.

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-18.2%
Operating margin
-22.6%
Return on equity
-16.8%
Liabilities / assets
25.9%
Revenue growth
+16.4%
R&D / revenue
77.5%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2011: revenue $31M, net income $-15M$31MFY11Fiscal year ending Dec 2012: revenue $25M, net income $-22M$25MFY12Fiscal year ending Dec 2013: revenue $38M, net income $-26M$38MFY13Fiscal year ending Dec 2014: revenue $40M, net income $-50M$40MFY14Fiscal year ending Dec 2015: revenue $26M, net income $-85M$26MFY15Fiscal year ending Dec 2016: revenue $25M, net income $-103M$25MFY16Fiscal year ending Dec 2017: revenue $38M, net income $-39M$38MFY17Fiscal year ending Dec 2018: revenue $44M, net income $-8M$44MFY18
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2018$44M+16.4%$-10M$-8M-18.2%
Dec 2017$38M+51.7%$-41M$-39M-102.4%
Dec 2016$25M-2.9%$-103M$-103M-409.9%
Dec 2015$26M-34.5%$-86M$-85M-329.8%
Dec 2014$40M+4.7%$-51M$-50M-126.4%
Dec 2013$38M+53.1%$-24M$-26M-69.0%
Dec 2012$25M-21.4%$-22M$-22M-90.1%
Dec 2011$31M—$-15M$-15M-47.9%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2018$-45M$1M$-46M$-0.21—
Dec 2017$-85M$1M$-86M$-1.04—
Dec 2016$-37M$1M$-38M$-3.14—
Dec 2015$-75M$1M$-77M$-2.84—
Dec 2014$-85M$2M$-86M$-1.69$0.00
Dec 2013$145M$1M$144M$-1.93$0.00
Dec 2012$-33M$1M$-34M$-21.30—
Dec 2011$-11M$2M$-14M$-15.40—

SEC filings

Official filings of OncoMed with the US Securities and Exchange Commission.

Annual results

Revenue
$44 M
Operating income
$-10 M
Net income
$-8 M

For year ending December-2018 · source: SEC filing

Balance sheet

Total assets
$65 M
Total liabilities
$17 M
Total equity
$48 M

As of December-2018

Insider trading at OncoMed#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
27
since
OncoMed: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jonathan D. RootDirectorTender in a change of control-121,020——0Form 4
filed Alicia J. HagerSVP and General CounselTender in a change of control-39,488——0Form 4
filed Perry A. KarsenDirectorTender in a change of control-80,500——0Form 4
filed Yvonne LiSee RemarksTender in a change of control-65,895——0Form 4
filed Deepika PakianathanDirectorTender in a change of controlindirect-1.99 M——0Form 4
filed John A. LewickiPresident and CEO, DirectorTender in a change of control-142,534——0Form 4
filed Robert StaggSee RemarksTender in a change of control-28,917——0Form 4
filed Jack W. LasersohnDirectorTender in a change of control-185,709——0Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

OncoMed scorecard#

Passes 7 of the 12 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (2 of 4). Fiscal year 2018.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth4 of 6
    • ✓Revenue grew in the newest year16.4%Revenue up 16.4% in fiscal 2018.
    • ✓Revenue up more than 5% a year over three years19.7%19.7% a year over the three years to fiscal 2018.
    • ✓Faster growth over three years than its peers' median19.7%19.7% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-0.21 vs -1.04Diluted EPS -0.21 in fiscal 2018 against -1.04 the year before (report's currency).
    • ✓Net income higher than five years earlier-$8 M-$8 M in fiscal 2018 against -$26 M in 2013.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2018.
  • Profitability2 of 4
    • ✗Profitable in the newest year-$8 MNet income -$8 M in fiscal 2018.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2018.
    • ✓Operating margin above its peers' median-22.6%-22.6% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-22.6%-22.6% in fiscal 2018 against -330.3% in 2015.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities5.0×Current ratio 5.04 at the end of fiscal 2018.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2018.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

OncoMed: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

OncoMed: statements by fiscal year
PeriodTrendFY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015FY 2014to Dec 31, 2014FY 2013to Dec 31, 2013FY 2012to Dec 31, 2012FY 2011to Dec 31, 2011
Income statement
Revenue4438252640382531
Research and development34601109376504040
General and administrative1817191914127.26.6
Operating expenses547912911190624747
Operating income−10−41−103−86−51−24−22−15
Interest expense and finance costs——————0.00.0
Income before tax−8.5−40−103−85−51−24−22−15
Income tax−0.4−1.10.00.0−0.51.90—
Net income including minority interests−8.1−39−103—————
Net income attributable to shareholders−8.1−39−103−85−50−26−22−15
Earnings per share, basic-0.21-1.04-3.14-2.84-1.69-1.93-21.30-15.40
Earnings per share, diluted-0.21-1.04-3.14-2.84-1.69-1.93-21.30-15.40
Shares, weighted average (diluted)3838333030141.01.0
Dividends per share————0.000.00——
Balance sheet
Cash and cash equivalents9.7133738282091612
Short-term investments489014811920410750—
Receivables—————0——
Other current assets1.91.72.53.31.7r2.51.1—
Current assets6410519023124131971—
Property, plant and equipment0.63.34.54.85.14.65.5—
Total assets6511019523824833480—
Accounts payable1.82.64.96.74.4r5.70.8—
Current liabilities13935653396220—
Total liabilities1715921923417121641—
Retained earnings−362−452−413−310−224−174−148—
Shareholders' equity48−49−233.676118−144−123
Total liabilities and equity6511019523824833480—
Shares outstanding3938373030291.1r—
Cash-flow statement
Depreciation and amortization1.71.71.81.61.41.41.41.2
Share-based compensation6.89.411116.21.70.80.8
Cash from operating activities−45−85−37−75−84r145−33−11
Capital expenditure−0.7−0.6−1.2−1.4−1.8−0.6−0.7−2.2
Cash from investing activities4157−3084−98r−58387.4
Shares issued—————21——
Dividends paid————00——
Cash from financing activities0.14.0651.82.1106−0.2−0.7
Change in cash−3.6−24−1.510−1811934.5−4.6
Report10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2018. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at OncoMed#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Delisting notice 1 · Restructuring 2 · Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 9 · Material agreement 2 · Agreement ended 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 11

OncoMed: events reported to the SEC
FiledWhat happenedFiling
Taken over and delistedChange in controlAcquisition or sale completedDirectors and officersShareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Material agreement8-K
Results announced8-K
Delisting notice8-K
RestructuringDirectors and officersMaterial agreement8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K/A
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K/A
Directors and officers8-K
Directors and officersResults announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Agreement ended8-K
Shareholder vote8-K
Results announced8-K
Restructuring8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Apr 23, 2019

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of OncoMed
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2013$22 MNo. 1$10 to $50 million1equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at OncoMed#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
99
2017–2018
Latest
39 people
2018-12-05
OncoMed: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2018···········3939
2017···60········60
OncoMed: latest layoffs
AnnouncedPeopleKindWhereSource
39 peopleRestructuring planSEC 8-K“In connection with the proposed Merger disclosed in Item 1.01 above, on December 4, 2018, the Board of Directors of the Company (the “Company Board”) approved a reduction to the Co…”Filing
60 peopleRestructuring planSEC 8-K“Under this plan, the Company plans to reduce its workforce by 60 employees (or 48%) to 64 employees.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How OncoMed compares in Biotechnology

  • Revenue$44 M · higher than 58% of 647
  • Net margin-18.2% · higher than 62% of 408
  • Revenue growth16.4% · higher than 59% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
OncoMed🇺🇸——-18.2%+16.4%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Annual results:
For year ending December-2018
Balance sheet:
As of December-2018
Profile updated:
Nov 16, 2026

Figures from SEC filing, Wikidata, Wikipedia, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at OncoMed? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show OncoMed's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about OncoMed? Suggest a correction